MeiraGTx Holdings PLC (MGTX)

Currency in USD
7.62
-0.33(-4.15%)
Closed·
After Hours
7.620.00(0.00%)
·
MGTX Scorecard
Full Analysis
Quickly burning through cash
MGTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.598.09
52 wk Range
3.858.98
Key Statistics
Prev. Close
7.95
Open
7.95
Day's Range
7.59-8.09
52 wk Range
3.85-8.98
Volume
274.34K
Average Volume (3m)
557.57K
1-Year Change
79.05%
Book Value / Share
0.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MGTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
27.50
Upside
+260.89%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

MeiraGTx Holdings PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

MeiraGTx Holdings PLC Company Profile

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

MeiraGTx Holdings PLC SWOT Analysis


Gene Therapy Pionee
MeiraGTx's diverse pipeline spans treatments for xerostomia, X-linked retinitis pigmentosa, and Parkinson's disease, positioning it as a leader in gene therapy innovation
Financial Fortification
Explore how MeiraGTx secured $50 million in equity financing, including a significant $30 million investment from pharmaceutical giant Sanofi, bolstering its research capabilities
Regulatory Milestones
Learn about MeiraGTx's crucial FDA alignment for its xerostomia treatment, potentially supporting a Biologics License Application by 2026 and accelerating market entry
Market Valuation
Analyst price targets range from $11 to $36, suggesting significant upside potential despite the stock's current "Speculative Risk" qualifier and recent price target adjustment
Read full SWOT analysis

Compare MGTX to Peers and Sector

Metrics to compare
MGTX
Peers
Sector
Relationship
P/E Ratio
−3.7x−1.1x−0.5x
PEG Ratio
0.05−0.060.00
Price/Book
18.5x2.2x2.6x
Price / LTM Sales
17.7x9.2x3.3x
Upside (Analyst Target)
233.3%307.6%43.5%
Fair Value Upside
Unlock18.5%6.9%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 27.50
(+260.89% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-- / -0.4733
Revenue / Forecast
-- / 8.00M
EPS Revisions
Last 90 days

MGTX Income Statement

People Also Watch

3.52
ALT
-2.22%
6.07
EOLS
-4.71%
17.195
QBTS
-2.19%
6.790
FOLD
-2.02%

FAQ

What Stock Exchange Does MeiraGTx Trade On?

MeiraGTx is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for MeiraGTx?

The stock symbol for MeiraGTx is "MGTX."

What Is the MeiraGTx Market Cap?

As of today, MeiraGTx market cap is 611.58M.

What Is MeiraGTx's Earnings Per Share (TTM)?

The MeiraGTx EPS (TTM) is -2.27.

When Is the Next MeiraGTx Earnings Date?

MeiraGTx will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is MGTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has MeiraGTx Stock Split?

MeiraGTx has split 0 times.

How Many Employees Does MeiraGTx Have?

MeiraGTx has 372 employees.

What is the current trading status of MeiraGTx (MGTX)?

As of 07 Aug 2025, MeiraGTx (MGTX) is trading at a price of 7.62, with a previous close of 7.95. The stock has fluctuated within a day range of 7.59 to 8.09, while its 52-week range spans from 3.85 to 8.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.